INT201129

Context Info Confidence 0.11 First Reported 2007 Last Reported 2010 Negated 0 Speculated 0 Reported most in Body Documents 5 Total Number 5 Disease Relevance 1.09 Pain Relevance 0.13

plasma membrane (QRFPR) signal transducer activity (QRFPR)

Anatomy Link Frequency capsules 1 internal 1 QRFPR (Homo sapiens)

Pain Link Frequency Relevance Heat Bioavailability 8 90.32 headache 28 85.60 pruritus 8 5.00 Pain 5 5.00 abdominal pain 4 5.00 tolerance 1 5.00

Disease Link Frequency Relevance Heat Malaria 103 98.64 Obesity 21 98.20 Headache 28 85.60 Dizziness 41 83.36 Arrhythmias 2 Under Development 16 79.52 Vomiting 34 79.44 Otitis Media 4 78.68 Diarrhoea 12 77.68 Disease 14 53.12 Toxicity 28 33.80

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

These sorts of studies do not tell researchers anything about the efficacy of the drug in treating malaria, but the results are absolutely essential before trials can be done that do test efficacy in people with malaria. 126 healthy volunteers were recruited into the study, and each received capsules containing a different dosage of either AQ-13 or CQ.

AQ-13 Binding (dosage) of in capsules associated with malaria

1) Confidence 0.11 Published 2007 Journal PLoS Clinical Trials Section Abstract Doc Link PMC1764434 Disease Relevance 0.65 Pain Relevance 0.09

Because the major metabolite of AQ-13 (mono-N-dealkylated AQ-13) is not active against CQ-resistant parasites, this adjustment was based on the AUC?

AQ-13 Binding (metabolite) of

2) Confidence 0.11 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1764434 Disease Relevance 0 Pain Relevance 0.05

Quantitation was based on the peak:area ratios for AQ-13, CQ, and their metabolites in relation to the internal standard [26].

AQ-13 Binding (ratios) of in internal

3) Confidence 0.11 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1764434 Disease Relevance 0.08 Pain Relevance 0

Based on age, sex, race, weight, BMI, and the baseline QTc interval, there were no significant differences between volunteers randomized to AQ-13 versus CQ (Table 1).

AQ-13 Binding (randomized) of associated with obesity

4) Confidence 0.11 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1764434 Disease Relevance 0.26 Pain Relevance 0

Quite a few made specific mention of anti-malarial drugs, either providing a description or their actual name; when shown samples of SP and AS-AQ they recognized them and could say they were for malaria - either treatment or prevention.

AS-AQ Binding (recognized) of associated with malaria

5) Confidence 0.00 Published 2010 Journal Malar J Section Body Doc Link PMC2817700 Disease Relevance 0.10 Pain Relevance 0

General Comments

This test has worked.